Signet Therapeutics to Showcase Breakthrough Diffuse Gastric Cancer Drug SIGX1094 at T20+ China Future of Pharma Summit

From July 24 to 26, the T20+ | China's Future Path for New Drugs Conference will be grandly held in Suzhou. With the theme of "Standing at the Forefront of Science and Technology, Seeking Breakthrough Forces," this conference directly addresses pain points such as pharmaceutical enterprises' transformation and innovation ecosystem construction across the upstream and downstream chains. Amidst the interweaving of policy, technology, capital, and globalization, it seeks opportunities of the times.

Signet Therapeutics was invited to participate as a pioneer in the global "organoid + AI" drug discovery field.Dr. Haisheng Zhang, founder and CEO of the company, will deliver a keynote speech titled "Organoids + AI Empowering the Development of the First Targeted Drug for Diffuse Gastric Cancer" on July 26 from 13:55 to 14:20., and the company has set up a special booth at B06. Welcome to visit and exchange!

This speech will focus on sharing the breakthrough progress made by Signet Therapeutics in the field of innovative drug development using its unique "organoid + AI" platform. Dr. Haisheng Zhang will detail the development journey of SIGX1094, the world's first targeted drug for diffuse gastric cancer developed based on the "organoid + AI" platform. As the world’s first targeted drug for diffuse gastric cancer, it has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and is currently undergoing Phase I clinical trials at the Beijing Cancer Hospital.

Meeting NameT20+ | The Future of China's New Drug Development Conference

Sharing Time: July 26th, 13:55-14:20

Venue of the Conference：Suzhou Jinji Lake Kempinski Hotel

Booth Number：B06

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a national high-tech enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since completed nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China’s NMPA, as well as orphan drug designation and fast track status from the U.S. FDA. Phase I clinical trials are currently underway at Peking University Cancer Hospital.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Investigating Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. By integrating AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has approximately 1500 square meters of R&D space and 500 square meters of animal laboratory facilities. SIGNET's organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.